|4Aug 15, 4:40 PM ET

GEORGIOU GEORGE 4

4 · Aeglea BioTherapeutics, Inc. · Filed Aug 15, 2018

Insider Transaction Report

Form 4
Period: 2018-08-13
Transactions
  • Exercise/Conversion

    Common Stock

    2018-08-13$4.73/sh+20,000$94,600175,861 total
  • Exercise/Conversion

    Common Stock

    2018-08-13$7.28/sh+17,333$126,184155,861 total
  • Exercise/Conversion

    Director Stock Option (right to buy)

    2018-08-1317,3336,667 total
    Exercise: $7.28Exp: 2026-05-16Common Stock (17,333 underlying)
  • Exercise/Conversion

    Director Stock Option (right to buy)

    2018-08-1320,00010,000 total
    Exercise: $4.73Exp: 2027-11-30Common Stock (20,000 underlying)
Footnotes (2)
  • [F1]The stock option vested and became exercisable, and shall continue to vest and become exercisable, in 36 equal monthly installments beginning on June 17, 2016, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date.
  • [F2]The stock option vested and became exercisable, and shall continue to vest and become exercisable, in 12 equal monthly installments beginning on January 1, 2018 until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date.

Documents

1 file
  • 4
    doc1.xmlPrimary

    FORM 4